Yescarta market seen growing on leukemia demand and personalized medicine

Nov. 20, 2026
Yescarta market seen growing on leukemia demand and personalized medicine
By AI, Created 17:00 UTC, Nov 20, 2026, AGP -

The Business Research Company says the Yescarta market should keep expanding through 2026, driven by rising leukemia cases, broader use of CAR-T therapy and more personalized cancer treatment. North America held the largest share in 2025 and is expected to stay in front next year.

Why it matters: - Yescarta is part of the fast-growing CAR-T cancer treatment market, where demand is rising as more patients and doctors turn to personalized therapies. - The market outlook matters because growth could expand access to advanced blood cancer treatment and support further investment in next-generation cell therapies.

What happened: - The Business Research Company published a market outlook for Yescarta, the autologous T-cell therapy also known as axicabtagene ciloleucel. - The report says the Yescarta market is on a growth path through 2026. - The report centers on demand in blood cancers, especially relapsed or refractory large B-cell lymphoma and primary mediastinal B-cell lymphoma. - The company also released a sample report and a full report link for the market analysis: More information and the full report.

The details: - Yescarta uses genetically engineered patient T cells to target CD19 on malignant B cells. - The report points to breakthroughs in genetic engineering, rising hematologic cancer incidence and the expansion of specialized cancer centers as key growth drivers. - The report says early results in refractory lymphoma created a foundation for broader use. - Future growth is expected to come from use in additional cancer types, investment in next-generation CAR constructs, and more efficient manufacturing. - Earlier use in treatment lines and lower-cost cell therapy methods are also expected to support demand. - The report highlights wider CAR-T use in oncology, more funding for cell and gene therapy platforms, greater reliance on autologous immunotherapies and a focus on long-term remission as major trends. - Leukemia cases in the U.S. rose to 62,770 in 2024 from 59,610 in 2023, according to the American Cancer Society. - Personalized medicine is also supporting the market as therapies are increasingly matched to a patient’s genetic and tumor profile. - The Personalized Medicine Coalition reported that the FDA approved 16 personalized therapies in 2023, up from six in 2022, including seven cancer drugs. - A growing pipeline of clinical trials is adding evidence for CAR-T therapies and supporting adoption by providers. - The Association of the British Pharmaceutical Industry reported that pharmaceutical industry-led trials in the U.K. rose to 426 in 2023 from 411 in 2022. - North America held the largest share of the Yescarta market in 2025 and is expected to keep that lead in 2026. - The report also covers Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East and Africa.

Between the lines: - The report ties Yescarta’s outlook to a broader shift in oncology toward individualized treatment and earlier intervention. - Manufacturing scale-up and cost reduction remain important because CAR-T therapies are complex and resource-intensive. - The regional leadership of North America suggests the market is still concentrated where specialist cancer centers, reimbursement systems and clinical adoption are strongest.

What's next: - The report expects more market growth if Yescarta and similar CAR-T therapies move into earlier stages of treatment and additional cancer indications. - Investment in manufacturing, trial activity and next-generation CAR designs will likely shape how fast the market expands. - The company’s 2026 report package adds TAM analysis, forecasting dashboards, company scoring tools and updated graphics for tracking the market.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Culture Zone! UK

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Culture Zone! UK

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.